SPI Pharma's vaccine manufacturing partner Q-Vant achieves EXCiPACT certification
Wilmington, Delaware - September 1, 2026
SPI Pharma is pleased to announce that its strategic manufacturing partner, Q-Vant, has successfully achieved EXCiPACT certification, an internationally recognized standard for pharmaceutical excipient manufacturers.
The certification underscores Q-Vant's commitment to robust quality systems, Good Manufacturing Practices (GMP), and operational excellence. As the manufacturing partner for SPI Pharma's portfolio of saponin-based vaccine adjuvants for both human and veterinary health, Q-Vant plays a key role in delivering high-quality, reliable solutions to vaccine developers worldwide. Together, SPI Pharma and Q-Vant are the first to offer cGMP QS-21 produced from a sustainable biomass source, combining environmental responsibility with a secure, scalable and secure supply of one of the industry's most critical vaccine adjuvants.
As demand for advanced vaccine technologies continues to grow, ensuring secure and resilient access to critical raw materials has become increasingly important. The EXCiPACT certification further strengthens confidence in the manufacturing processes, quality systems, and long-term supply capabilities supporting SPI Pharma's vaccine adjuvant portfolio. Our adjuvant portfolio is already available to customers today, with GMP-grade QS-21 GH and VAC Saponin available now. Valens™ QS-21 XP, our latest addition, is expected to be commercially available by December 2026.
The achievement also represents an important step toward strengthening global pandemic preparedness. Expanding qualified manufacturing capacity for critical vaccine components, while diversifying supply through sustainable sourcing, helps improve the resilience of global vaccine supply chains and supports a faster response to future infectious disease outbreaks.
"Our partnership with Q-Vant is built on a shared commitment to quality, innovation, and sustainability," said Ariana Meirelles, Marketing Manager for Adjuvants, SPI Pharma. "This certification demonstrates the strength of our manufacturing network and reinforces our ability to support vaccine developers with reliable, high-quality adjuvant solutions for both routine immunization programs and future public health needs."
SPI Pharma and Q-Vant remain committed to advancing innovative adjuvant technologies while ensuring the highest standards of quality, regulatory compliance, sustainability, and supply reliability. Together, the companies will continue supporting vaccine developers worldwide in bringing the next generation of vaccines to patients and animals around the globe.
About SPI Pharma
SPI Pharma is a global supplier of pharmaceutical ingredients, drug delivery systems, and API solutions serving customers across human and animal health. SPI Pharma is a Division of ABF Ingredients Ltd who are part of Associated British Foods plc, a diversified international food, ingredient, and retail group.
About Q-Vant Biosciences
Q-VANT Biosciences is a biotechnology company focused on the development and manufacture of next-generation saponin-based vaccine adjuvants. Through its proprietary technology platform, Q-VANT has transformed the supply of QS-21, addressing longstanding challenges related to security of supply, quality, and scalability for vaccine developers and manufacturers. By enabling sustainable production at a scale capable of supporting billions of vaccine doses, Q-VANT is helping advance global efforts to prevent and eradicate disease through innovative vaccine solutions.
Q-Vant Biosciences | Next-Generation Saponin Adjuvants
For further enquiries, please contact:
[email protected]